Viking Therapeutics Inc Cash Flow Conversion Efficiency
Viking Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Viking Therapeutics Inc (VKTX) has a cash flow conversion efficiency ratio of -0.307x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-125.17 Million) by net assets ($408.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VKTX company net worth for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Viking Therapeutics Inc (2013–2025)
Cash flow conversion efficiency of Viking Therapeutics Inc from 2013 to 2025. This chart illustrates how Viking Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VKTX stock price for real-time trading data and today's change.
Viking Therapeutics Inc Cash Flow Conversion Ratio Explained
Viking Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Viking Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viking Therapeutics Inc ranked by their cash flow conversion efficiency. Review financial agility of Viking Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Independence Realty Trust Inc
NYSE:IRT
|
0.016x |
|
H&E Equipment Services Inc
NASDAQ:HEES
|
0.162x |
|
Renasant Corporation
NYSE:RNST
|
0.035x |
|
Cofinimmo SA
BR:COFB
|
0.014x |
|
Xinjiang Tianshan Cement Co Ltd
SHE:000877
|
0.033x |
|
Adata Technology Co Ltd
TWO:3260
|
-0.077x |
|
Strauss Group
TA:STRS
|
0.114x |
|
CMB.TECH NV
BR:CMBT
|
0.054x |
Annual Cash Flow Conversion Efficiency for Viking Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Viking Therapeutics Inc from 2013 to 2025. Also see balance sheet size of Viking Therapeutics Inc for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $639.06 Million | $-278.69 Million | -0.436x | -337.27% |
| 2024-12-31 | $880.28 Million | $-87.79 Million | -0.100x | +52.64% |
| 2023-12-31 | $348.42 Million | $-73.38 Million | -0.211x | +36.76% |
| 2022-12-31 | $145.32 Million | $-48.40 Million | -0.333x | -41.29% |
| 2021-12-31 | $201.88 Million | $-47.59 Million | -0.236x | -164.47% |
| 2020-12-31 | $244.34 Million | $-21.78 Million | -0.089x | +0.22% |
| 2019-12-31 | $277.12 Million | $-24.75 Million | -0.089x | -41.80% |
| 2018-12-31 | $297.75 Million | $-18.75 Million | -0.063x | +94.25% |
| 2017-12-31 | $13.46 Million | $-14.76 Million | -1.096x | +20.38% |
| 2016-12-31 | $8.04 Million | $-11.07 Million | -1.377x | -37.55% |
| 2015-12-31 | $8.72 Million | $-8.73 Million | -1.001x | -1491.52% |
| 2014-12-31 | $-22.13 Million | $-1.59 Million | 0.072x | -76.96% |
| 2013-12-31 | $-250.60K | $-78.23K | 0.312x | -- |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more